Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04585997




Registration number
NCT04585997
Ethics application status
Date submitted
30/09/2020
Date registered
14/10/2020
Date last updated
14/10/2020

Titles & IDs
Public title
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
Scientific title
How to "Choosebetweenamab" for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma.
Secondary ID [1] 0 0
18/08/15/3.01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Eosinophilic Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Blood 0 0 0 0
Haematological diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Mepolizumab
Treatment: Drugs - Omalizumab

Active comparator: Mepolizumab - Mepolizumab

Active comparator: Omalizumab - Omalizumab


Treatment: Drugs: Mepolizumab
Mepolizumab 100mg subcutaneous injection monthly for 6 months

Treatment: Drugs: Omalizumab
Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
ACQ5
Timepoint [1] 0 0
Assessed after 6 months treatment
Secondary outcome [1] 0 0
Exacerbations
Timepoint [1] 0 0
every month up to 6 months after treatment commenced
Secondary outcome [2] 0 0
Time to first exacerbation reported, by patient or health provider
Timepoint [2] 0 0
every month up to 6 months after treatment commenced
Secondary outcome [3] 0 0
Hospital admissions
Timepoint [3] 0 0
every month up to 6 months after treatment commenced
Secondary outcome [4] 0 0
Oral corticosteroids
Timepoint [4] 0 0
every month up to 6 months after treatment commenced
Secondary outcome [5] 0 0
Spirometry
Timepoint [5] 0 0
every month up to 6 months after treatment commenced
Secondary outcome [6] 0 0
Continuing treatment
Timepoint [6] 0 0
6 months post intervention
Secondary outcome [7] 0 0
Adverse events
Timepoint [7] 0 0
every month up to 6 months after treatment commenced
Secondary outcome [8] 0 0
Emergency department presentation
Timepoint [8] 0 0
every month up to 6 months after treatment commenced
Secondary outcome [9] 0 0
Overall dose of oral corticosteroids
Timepoint [9] 0 0
6 months post intervention
Secondary outcome [10] 0 0
Change in gene expression measured by single cell RNA sequencing of peripheral blood cells (ISS 11066)
Timepoint [10] 0 0
Measured prior to treatment and clinical outcomes at 6 months after treatment

Eligibility
Key inclusion criteria
* Participants must have a duration of asthma of greater than one year.
* They must have confirmed asthma defined as: (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12%, and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days.
* They must have evidence of poor asthma control despite optimal ICS and long acting beta agonist (LABA), be treated by a respiratory physician or immunologist, and have demonstrated acceptable adherence and inhaler technique. Poor control is defined as: evidence of an FEV1 <80% of predicted in the last year on at least one occasion; treatment with OCS, either daily for at least 6 weeks, or a cumulative dose of OCS of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated.
* In addition they must demonstrate an: (a) an Asthma Control Questionnaire (ACQ-5)38 score of at least 2.0, as assessed in the previous month, and (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, or 1 severe asthma exacerbation, requiring documented use of OCS initiated or increased for at least 3 days, or parenteral corticosteroids prescribed/supervised by a physician.
* They must also demonstrate evidence of a dual allergic/ eosinophilic phenotype. This is defined as: a total serum IgE >30IU/mL, past or current evidence of atopy documented by skin prick testing or radioallergosorbent assay, and the participant must have a blood eosinophil count greater than or equal to 300 cells per microlitre in the last 6 weeks.
Minimum age
12 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Do not fulfil inclusion criteria
* Unable to attend appointments
* Significant psychiatric illness

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2022
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
John Hunter Hospital - New Lambton
Recruitment postcode(s) [1] 0 0
2305 - New Lambton

Funding & Sponsors
Primary sponsor type
Other
Name
University of Newcastle, Australia
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
GlaxoSmithKline
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Mepolizumab is an anti-interleukin-5 ( IL-5) monoclonal antibody that neutralizes IL-5 and reduces eosinophil counts in both sputum and blood. Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody (mAb) used in the treatment of severe allergic eosinophilic asthma

The investigators propose that in patients with the dual phenotypes of severe allergic and eosinophilic asthma, that Mepolizumab is as effective as Omalizumab. However, this trial will also identify key clinical biomarkers that will clarify which patients will respond best to each of these interventions.

This study will be the first direct clinical comparison of these agents and will apply expert clinical characterization, along with cutting edge biotechnology to better inform treatment choices for severe asthma. This is an important and urgent management problem facing the Australian pharmaceutical scheme, where imprecision in prescribing will result in reduced clinical effectiveness as well as substantial and sustained costs.
Trial website
https://clinicaltrials.gov/study/NCT04585997
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Peter Wark, MBBS/PhD
Address 0 0
University of Newcastle and Hunter New England Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Peter Wark, MBBS/PhD
Address 0 0
Country 0 0
Phone 0 0
(02) 40420110
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04585997